CrossAssetDataThe Company File
···
PAHC

Phibro Animal Health Corporation

Phibro Animal Health Corporation is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Teaneck, NJ. In its latest annual figures on file, for the fiscal year ended 2025-06-30, it reported revenue of $1.3 billion and a profit of $48 million (its filed statements).

Product business Pharmaceutical Preparations Teaneck, NJ filings since 1998 9 of 9 filed
Ask the desk about PAHC → Compare PAHC with RARE → Price chart on TradingView ↗ Full EDGAR file ↗ Watch PAHC →

Sector peers: RARESUPNLGNDACAD

6.3/10headline grade
vs its business-model standard
7.9/10past 6.4/10present 4.7/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2834, Pharmaceutical Preparations); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 6.3 out of ten, 9 of 9 metrics filed: past 7.9 out of ten, present 6.4 out of ten, future 4.7 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 8.2 out of ten. No warning events in its filings since 2017. 82nd percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 8.2 out of ten. +11.3% a year over 7 filed years; profitable in 7 of 7. 82nd percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Shareholder treatment (past): 6.8 out of ten. Share count grew 0.4% a year. 25% of cash flow returned. Insiders: 61 sales, 1 purchases. 68th percentile among 80 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Financial health (present): 6.6 out of ten. ROE 26%: 26¢ of profit per shareholder dollar. Leverage 74%: owes 74¢ per asset dollar. 66th percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 7.6 out of ten. top 24% of 314 in its family; net margin 6.6%. 76th percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 4.2 out of ten. bottom 42% of 315 in its family for leadership; chief executive since 2026. 42nd percentile among 315 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
  • Room to expand (future): 2.8 out of ten. bottom 28% of 272 in its family for room to expand. 28th percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 6.3 out of ten. top 37% of 307 in its family for growth drivers. 63rd percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Expectations vs reality (future): 6.5 out of ten. top 35% of 234 in its family for expectations against reality. 65th percentile among 234 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).

The filing record

Newest annual report: Form 10-K filed 2026-08-26 for the period ended 2026-06-30 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-05-06 for the period ended 2026-03-31 (on EDGAR). Newest results release: Form 8-K filed 2026-08-26 (on EDGAR). Newest filing: Form ARS, 2026-09-18. Filings on record since 1998. Read from EDGAR 2026-10-12.

Where the revenue comes from

Lines of business in fiscal 2026: Animal Health 77%, Mineral Nutrition 19%, Performance Products 5%. By geography: United States 58%, Latin America and Canada 22%, Europe, Middle East and Africa 12%, Asia Pacific 7%. As tagged in its annual report (Form 10-K, filed 2026-08-26).

Who runs it

Bendheim, Daniel M (President and CEO); Bendheim, Jack (Executive Chairman); Escudero, Lisa Ann (Senior Vice President, Human Resources.); Weinstein, Judith (Senior Vice President, General Counsel and Corporate Secretary.); Andolino, Anthony (Vice President Finance and Treasurer. Exhibit List - Exhibit 24.1 Power of Attorney); David, Glenn (Chief Financial Officer); Miller, Larry Lee (Chief Operating Officer); Rodriguez, Patrick (VP Finance and Treasurer); Bendheim, Jonathan (director); Corcoran, E Thomas (director). 10 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.